Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

With Robert F. Kennedy Jr. slated to take the top spot at the U.S. | RFK Jr. has previously expressed a desire to put a stop ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

More than three years into a lawsuit accusing competitor Natera of disparaging its cancer blood test, Guardant Health has ...

Indian drugmaker Lupin is recalling more than 600,000 bottles of the high blood pressure and heart failure drug ramipril due ...

Hovione, a Portuguese CDMO that specializes in spray drying, completed multiyear expansion projects at manufacturing ...

German CDMO Adragos Pharma has been on a growth tear this year, drafting plans to boost capacity in Japan, upgrading a ...

Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee ( | The ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer antidepressant, reduced bouts of cataplexy and other narcolepsy symptoms in ...